Furthermore, it has been shown that additional therapy adding an SGLT2 inhibitor and an ARNI leads to an extra benefit and increased life expectancy compared with conventional therapy with an ACE inhibitor, angiotensin receptor blocker (ARB) or beta-blocker, which is dependent on the patient's age at diagnosis of HF [44]. The gene discussed is ACE; the disease is hydrops fetalis.